Invasive bladder carcinoma: A pilot study of conservative treatment with accelerated radiotherapy and concomitant cisplatin

International Journal of Cancer

Volumn 96, Issue 6, 2001, Pages 350-355

  Zouhair, Abderrahim ^a   Ozsahin, Mahmut ^a   Schneider, Dominique ^a   Bauer, Jean ^b   Jichlinski, Patrice ^b   Roth, Arnaud ^b   Douglas, Pelham ^c   Miralbell, Raymond ^c,d  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CLINIQUE DE GENOLIER   (Switzerland)

^d Division de Radio oncologie   (Switzerland)

Author keywords

Accelerated radiotherapy; Bladder cancer; Concomitant cisplatin

Indexed keywords

CISPLATIN; CREATININE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CREATININE CLEARANCE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MALE; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; SAFETY; SCORING SYSTEM; TREATMENT OUTCOME; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 0035924216     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1034     Document Type: Article

References (19)

1. Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire
2. Organ-sparing treatment of advanced bladder cancer: A 10-year experience
3. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: A prospective study
4. Bladder preservation by combined modality therapy for invasive bladder cancer
5. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12
6. An update of combined modality therapy for patients with muscle invading bladder cancer using selective bladder preservation or cystectomy
7. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation
8. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03
9. Treatment of advanced bladder cancer category T2, T3, T4a
10. Predictive value of potential doubling time for radiotherapy of head and neck tumor patients: Results from the EORTC Cooperative Trial 22851
11. Tumor cell kinetics, local tumor control, and accelerated radiotherapy: A preliminary report
12. The hazard of accelerated tumor clonogen repopulation during radiotherapy
13. Dose fractionation and tumor repopulation in radiotherapy for bladder carcinoma
14. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer
15. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003
16. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
17. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomised multi-centre trial
18. A feasibility study of accelerated fractionation in radiotherapy of carcinoma of the urinary bladder
19. Radiotherapy for T2 and T3 carcinoma of the bladder: The influence of overall treatment time